Full-year results were 7% ahead of the August trading update. Revenue growth of 27% was driven by Vitamin D, up c55%, and sterling's depreciation, which contributed c11% to growth. A higher final dividend together with a 20p special dividend implies a combined yield of 2.9%. Management is confident that Siemens will launch its troponin-based assay contributing to and largely replacing lost NT proBNP royalties in FY 2018. We have increased our target price to 1450p to reflect a 5% EPS upgrade
17 Oct 2016
FY 2016 results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY 2016 results
Bioventix Plc (BVXP:LON) | 4,600 0 0.0% | Mkt Cap: 240.1m
- Published:
17 Oct 2016 -
Author:
Mark Brewer | Cavendish Research -
Pages:
16
Full-year results were 7% ahead of the August trading update. Revenue growth of 27% was driven by Vitamin D, up c55%, and sterling's depreciation, which contributed c11% to growth. A higher final dividend together with a 20p special dividend implies a combined yield of 2.9%. Management is confident that Siemens will launch its troponin-based assay contributing to and largely replacing lost NT proBNP royalties in FY 2018. We have increased our target price to 1450p to reflect a 5% EPS upgrade